MapLight Therapeutics (MPLT) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oculis is the larger company by market cap ($520.4 million vs $504.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MPLT | OCS |
|---|---|---|
| Share price | $9.08 | $8.45 |
| Market cap | $504.63M | $520.42M |
| 1-day change | -2.99% | -0.59% |
| YTD return | -46.71% | -57.44% |
| 1-year return | — | -55.40% |
| 5-year return | — | -13.44% |
| EPS (TTM) | $-6.25 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.43 | $34.48 |
| 52-week low | $8.92 | $8.30 |
| Distance from 52-week high | -77.54% | -75.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +192.29% | +331.83% |
| Average volume | 858.68K | 258.13K |
| Shares outstanding | 52.85M | 61.59M |
| Employees | 133 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
MPLT vs OCS FAQ
Which is bigger, MapLight Therapeutics or Oculis?
Oculis (OCS) is larger, with a market capitalization of $520.42M compared with $504.63M for MapLight Therapeutics (MPLT).
Are MapLight Therapeutics and Oculis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.